Breath Diagnostics Receives FDA Breakthrough Device Designation for OneBreath Platform to Assess Postoperative Pneumonia Risk
核心洞察
Breath Diagnostics, Inc. (搜索) received FDA Breakthrough Device Designation for its OneBreath (搜索) platform, which analyzes exhaled volatile organic compounds (搜索) to identify patients at elevated risk of postoperative pneumonia (搜索) following elective cardiac surgery.
The OneBreath (搜索) platform represents the first FDA Breakthrough Device to apply liquid chromatography-mass spectrometry (LC-MS) based molecular analysis to human breath, completing analysis in approximately ten minutes from a single breath sample.
The designation provides prioritized FDA interaction and enhanced communication to support more efficient development and review, though it does not guarantee shortened approval timelines or final approval.
Breath Diagnostics, Inc. (搜索) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its OneBreath (搜索) platform, marking a significant milestone for breath-based molecular diagnostics in perioperative care. The designation applies to OneBreath as an in vitro diagnostic intended for qualitative assessment of exhaled volatile organic compounds (搜索) from a single pre-operative breath specimen to aid in risk stratification for adult patients scheduled for elective cardiac surgery.
Revolutionary Breath Analysis Technology
The OneBreath (搜索) platform distinguishes itself through its use of liquid chromatography-mass spectrometry (LC-MS) for direct molecular analysis of human breath. According to CEO Ivan Lo, "To our knowledge, OneBreath is the first FDA Breakthrough Device to apply LC-MS–based molecular analysis to human breath. Most breath technologies rely on indirect signals or sensors. Our platform operates at the molecular level, directly measuring defined chemical species with high analytical specificity, orthogonal validation, and broad linearity."
The system features a single-breath sampling design where patients provide one exhaled breath that is subsequently analyzed using LC-MS technology. The analytical workflow is designed to be completed in approximately ten minutes, supporting efficient integration into perioperative clinical settings without adding burden to patients or care teams.
Clinical Application and Regulatory Framework
The FDA's Breakthrough Device designation is based on evidence demonstrating that OneBreath (搜索) has the potential to identify patients at elevated risk of developing postoperative pneumonia (搜索) through qualitative molecular analysis of exhaled breath. The FDA grants this designation to a limited set of qualifying medical devices that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases than current options.
As specified in the FDA grant, OneBreath (搜索) is intended to be used in conjunction with clinical evaluation and standard risk assessment tools. The system does not identify specific pathogens and is not intended to diagnose pneumonia. Analysis must be performed by qualified laboratory personnel in an appropriately equipped clinical laboratory, and the device is for prescription use only.
Scientific Rationale and Platform Potential
Lo emphasized the biological basis for breath-based diagnostics, stating, "For years, researchers and clinicians have recognized that breath may provide one of the earliest and most dynamic readouts of human biology. A single exhaled breath is simple, fast, and entirely non-invasive — qualities that may make patients more willing to undergo testing compared with blood draws or other sample types such as urine or stool."
The CEO explained that unlike blood, which is filtered and metabolized by organs such as the liver and kidneys, breath contains volatile organic compounds (搜索) associated with biological processes, including inflammation and metabolic activity. This characteristic potentially enables earlier disease risk detection and more frequent monitoring.
The OneBreath (搜索) platform captures orthogonal layers of molecular evidence from exhaled VOCs, enabling qualitative assessment across a wide dynamic range. Breath Diagnostics believes this architecture positions OneBreath not as a single-use assay, but as a scalable platform technology potentially capable of supporting future clinical applications.
Development and Regulatory Pathway
The company plans to leverage the Breakthrough Devices Program to continue working closely with the FDA as it advances OneBreath (搜索) through its development and regulatory pathway. Devices accepted into the program receive prioritized FDA interaction and enhanced communication to support more efficient development and review, with the goal of providing patients and healthcare providers more timely access to innovative technologies while maintaining the FDA's rigorous standards.
However, the company notes that Breakthrough Device designation is based on preliminary data and does not guarantee that the FDA review and approval process will be shortened or that an application will be approved. The OneBreath (搜索) system has not been cleared or approved by the FDA or any other regulatory authority and remains in the development stage, unavailable for clinical or commercial use.